Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06506227

Research on Key Technologies for Risk Prediction and Precise Diagnosis and Treatment of AIS Based on Epigene-phenotype

Research on Key Technologies for Risk Prediction and Precise Diagnosis and Treatment of Adolescent Idiopathic Scoliosis Based on Epigene-phenotype

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
2,000 (estimated)
Sponsor
The First Affiliated Hospital of Zhejiang Chinese Medical University · Academic / Other
Sex
All
Age
10 Years – 18 Years
Healthy volunteers
Accepted

Summary

Mining AIS biomarkers, elucidating the new mechanism of AIS pathogenicity, constructing risk prediction models, optimizing AIS precise diagnosis and treatment techniques, formulating precise diagnosis and treatment protocols and technical specifications for AIS combined with Chinese and Western medicine with independent intellectual property rights, and realizing the full coverage of Zhejiang Province by the end of 2026, so as to form the "Zhejiang experience" of AIS diagnosis and treatment.

Detailed description

Currently, there are problems of high genetic and phenotypic heterogeneity in AIS research, lack of in-depth epigenetic studies, and lack of clarity in pathogenic mechanisms. This project proposes to use EWAS technology, combined with a hybrid model of multidimensional and multimodal data fusion, to realize a multi-omics joint analysis, to clarify the amount of synergistic effects between multi-omics risk factors and AIS, to draw a map of modifiable risk factors, to clarify AIS biomarkers, and to reveal AIS To clarify the biomarkers of AIS and reveal the pathogenic mechanism of AIS. Currently, the clinical diagnosis and treatment of AIS is highly subjective and lacks objective and accurate risk prediction, which makes it easy to make wrong clinical decisions, resulting in insufficient, delayed or excessive treatment, missing the optimal time for treatment, and poor clinical efficacy. This project intends to establish a multi-dimensional and multi-modal dynamic database, use the unified model construction technology, combined with the sample imbalance model, to construct a unified and accurate prediction model for AIS, to perform clinical typing and risk stratification for AIS, to establish individualized and accurate diagnostic and treatment protocols for AIS, to improve the efficacy of AIS, to obtain high-quality clinical evidence, and to formulate industry-recognized clinical prevention and treatment standards, norms, and guidelines. Through mining AIS biomarkers, elucidating new mechanisms of AIS pathogenicity, constructing risk prediction models, optimizing AIS precision diagnosis and treatment techniques, and formulating precise diagnosis and treatment protocols and technical specifications for AIS combining Chinese and Western medicine with independent intellectual property rights, the project will achieve full coverage of Zhejiang Province by the end of 2026, forming the "Zhejiang experience" in AIS diagnosis and treatment. Zhejiang experience" will be formed in AIS diagnosis and treatment. The promotion of the results can realize the precision of AIS diagnosis and treatment, improve the efficacy of AIS treatment, reduce the incidence of severe scoliosis, reduce medical expenditure by billions of dollars, and alleviate the economic burden on families and society.

Conditions

Interventions

TypeNameDescription
BEHAVIORALLow risk experimental groupGuiding + Manipulation + Traditional Chinese Medicine
BEHAVIORALMedium risk experimental groupGuiding + Manipulation + Traditional Chinese Medicine + Specific Exercise Therapy + Orthopedic Braces
GENETICHigh risk experimental groupGuiding + Manipulation + Traditional Chinese Medicine + Specific Exercise Therapy + Orthopedic Braces + Specialized Inpatient Rehabilitation
BEHAVIORALControl group COBB 10-20°Specific Exercise Therapy
BEHAVIORALControl group COBB 20-45°Orthopedic Braces + Specific Exercise Therapy
BEHAVIORALControl group COBB >45°Orthopedic Braces + Specific Exercise Therapy + Recommended Surgery
OTHERExperimental group (AIS group)Molecular marker exploration and validation
OTHERControl group (healthy control)Molecular marker exploration and validation
OTHERControlled follow-up before and after AISConstruction and validation of AIS risk prediction model completed

Timeline

Start date
2024-09-01
Primary completion
2026-12-31
Completion
2026-12-31
First posted
2024-07-17
Last updated
2024-07-17

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06506227. Inclusion in this directory is not an endorsement.